Please Upload related files below
Fill in below.
Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.
Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.
Myriad released its first quarter 2025 financial results on May 6, 2025, revealing “revenue of $196 million declined by 3% year-over-year” and “pharmacogenomics revenue declined by 20% year-over-year due to UnitedHealthcare (UNH) reducing coverage of GeneSight®.” Additionally, the Company announced reduced financial guidance for 2025 “reflecting first quarter 2025 results and the current business outlook.”
Following this news, Myriad stock dropped on heavy trading volume on that day.